The heart as a target for oestrogens

Heart Lung and Circulation

Volumn 9, Issue 3, 2000, Pages 113-125

  Brown, Lindsay ^a   Hoong, Ian ^a   Doggrell, Sheila A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

Cardiovascular disease; Heart; Oestrogen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CALCIMYCIN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GESTAGEN; ION CHANNEL; LIPID; PIPERANOMETOZINE; PRAVASTATIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HEART; HEART DISEASE; HEART MUSCLE CELL; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; VASODILATATION;

EID: 0034481255     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2000.009003113.x     Document Type: Review

References (137)

1. Age at natural menopause and risk of cardiovascular disease
2. Age at natural menopause and mortality
3. Hormone replacement therapy and heart disease prevention. Experimentation trumps observation
4. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women
5. Do older women use estrogen replacement? Data from the duke established populations for epidemiologic studies of the elderly
6. Estrogen replacement therapy. A survey of older women's attitudes
7. Are women using postmenopausal estrogens? A community survey
8. Hormones and heart disease in women: Heart and estrogen/progestin replacement study in perspective
9. Alternatives to the use of estrogens in postmenopausal women
10. Design of the Women's Health Initiative clinical trial and observational study
11. Estrogen is associated with improved survival in aging women with congestive heart failure: Analysis of the vesnarinone studies
12. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
13. Estrogen replacement therapy and prognosis after first myocardial infarction
14. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
16. Hormone replacement therapy and cardiovascular disease
17. Hormone replacement therapy and cardiovascular disease
18. What have we learned and what questions remain?
19. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
21. Effects of estrogens or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
22. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
23. Estrogen and vascular system: More questions for the future
24. The protective effects of estrogen on the cardiovascular system
25. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women
26. The heart: A target organ for estradiol
27. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways
28. Estrogen and coronary heart disease in women
29. Modified LDL-mediated increases in endothelial layer permeability are attenuated with 17β-estradiol
30. Estrogens and lipid metabolism
31. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
32. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus
33. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
34. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
35. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women
36. Nitric oxide: A multifaceted modulator of cardiac contractility
37. Estrogen regulation of angiotensin-converting enzyme mRNA
38. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women
39. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women
40. Estrogen, natriuretic peptides and the renin-angiotensin system
41. 2 and NO in endothelial cells
42. 17-beta-oestradiol inhibits stimulated endothelin release in human vascular endothelial cells
43. 17β-Estradiol modulates endothelin-1 expression and release in human endothelial cells
44. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone
45. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women
46. Influence of the menstrual cycle on sympathetic activity, baroreflex sensitivity, and vascular transduction in young women
47. Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat
48. 17β-Estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo
49. Expression of oestrogen receptor α and β in rat heart: Role of local oestrogen synthesis
50. Genderspecific differences in expression of mRNAs for functional and structural proteins in rat ventricular myocardium
51. Gender-related differences in myocyte remodeling in progression to heart failure
52. Hypertrophic remodeling: Gender differences in the early response to left ventricular pressure overload
53. Cardiac morphology and function in senescent rats: Gender-related differences
54. Gender differences and aging: Effects in the human heart
55. Myocyte death in the failing human heart is gender dependent
56. Effects of transdermal 17β-estradiol on left ventricular anatomy and performance in hypertensive women
57. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms
58. Compensated cardiac hypertrophy: Arrhythmogenicity and the new myocardial phenotype. I. Fibrosis
59. Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways
60. 17Betaestradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth
61. Angiotensinogen converting enzyme inhibition modulates cardiac fibroblast growth
62. Estrogen and vascular resistance
63. Estrogen receptor-α gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration
64. Estrogens increase transcription of the human endothelial NO synthase gene. Analysis of the transcription factors involved
65. x release in human coronary artery endothelium
66. Estrogen and nitric oxide in vasculature
67. Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women
68. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women
69. Evidence for a difference in nitric oxide biosynthesis between healthy women and men
70. + channels
71. Effects of 17β-estradiol on coronary microvascular responses to endothelin-1
72. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects
73. Variant estrogen and progesterone receptor messages in human vascular smooth muscle
74. Localized expression of aromatase in human vascular tissues
75. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries
76. Short-term exposure to physiological levels of 17β-estradiol enhances endothelium-independent relaxation of porcine coronary artery
77. 2 in porcine coronary artery
78. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro
79. Acute effect of 17β-estradiol on coronary artery contractile responses to endothelin-1
80. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP
81. Effects of 17β-oestradiol on rat isolated coronary and mesenteric artery tone: Involvement of nitric oxide
82. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin
83. Serum vascular endothelial growth factor concentrations in postmenopausal women: The effect of hormone replacement therapy
84. Effect of estrogen on aortic function in postmenopausal women
85. Hormonal therapy increases arterial compliance in postmenopausal women
86. Sex-specific determinants of increased left ventricular mass in the tecumseh blood pressure study
87. Clinical pharmacology of estrogens: Cardiovascular actions and cardioprotective benefits of replacement therapy on postmenopausal women
88. Hypertension in women
89. Blood pressure and menopausal transition: The atherosclerosis risk in communities study (1987-95)
90. Effect of postmenopausal estrogen therapy on diastolic blood pressure and body weight
91. Prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women
92. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women
93. Rat models of hypertension, cardiac hypertrophy and failure
94. Estrogen attenuation of the development of hypertension in spontaneously hypertensive rats
95. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats
96. cp rats
97. Failure of women's hearts
98. Effect of postmenopausal hormones on inflammation-sensitive proteins
99. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women
100. Hormones and vasoprotection
101. Enhancement of postischemic myocardial function by chronic 17β-oestradiol treatment: Role of alterations in glucose metabolism
102. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease
103. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys
104. Mechanisms of estrogen-induced vasodilation: In vivo studies in canine coronary conductance and resistance arteries
105. Reactivity based coronary vasospasm independent of atherosclerosis in rhesus monkeys
106. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones
107. Electrocardiographic quantitation of ventricular repolarization
108. Sex differences in the evolution of the electrocardiographic QT interval with age
109. Incidence and risks associated with atrial fibrillation
110. Arrhythmias on ambulatory electrocardiographic monitoring in women without apparent heart diseases
111. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
112. Sex differences in risk of torsade de pointes with D,L-sotalol
113. The long QT syndrome: A prospective international study
114. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome
115. Antiarrhythmic effect and its underlying ionic mechanism of 17β-estradiol in cardiac myocytes
116. Effects of 17β-oestradiol on action potentials and ionic currents in male rat ventricular myocytes
117. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17β-oestradiol. Role of nitric oxide and calcium-activated potassium channels
118. Effects of gonadal steroids on ventricular repolarization and on the response to E4031
119. Sex hormones prolong the QT interval and downregulate potassium expression in the rabbit heart
120. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice
121. Cardiac and thromboembolic mortality among postmenopausal women with early-stage breast cancer in a radomized trial of adjuvant tamoxifen: The stockholm breast cancer study group
122. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
123. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
124. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
125. The effects of tibolone
126. Continuous combined hormone replacement therapy compared with tibolone
127. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women
128. Estrogen: Consequences and implications of human mutations in synthesis and action
129. Clinical Review 110: Cardiovascular actions of estrogens in men
130. Long-term estrogen therapy improves vascular function in male to female transsexuals
131. Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males
132. Long-term oestrogen treatment does not alter systemic arterial compliance and haemodynamics in biological males
133. Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in males
134. The coronary drug project: Initial findings leading to modification of its research protocol
135. Findings leading to discontinuation of the 2.5-mg/day estrogen group